Fulgent Genetics, Inc. (FLGT)

Market Cap	663.97M
Revenue (ttm)	292.45M
Net Income (ttm)	-40.78M
Shares Out	30.44M
EPS (ttm)	-1.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	263,896
Open	21.74
Previous Close	21.43
Day's Range	21.59 - 22.00
52-Week Range	14.57 - 25.11
Beta	1.07
Analysts	Buy
Price Target	24.00 (+9.89%)
Earnings Date	Aug 1, 2025

About FLGT

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive he...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Sep 29, 2016
• Employees: 1,313
• Stock Exchange: NASDAQ
• Ticker Symbol: FLGT
• Website: https://www.fulgentgenetics.com

Financial Performance

In 2024, Fulgent Genetics's revenue was $283.47 million, a decrease of -1.99% compared to the previous year's $289.21 million. Losses were -$42.71 million, -74.55% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for FLGT stock is "Buy." The 12-month stock price forecast is $24.0, which is an increase of 9.89% from the latest price.

Price Target

$24.0

(9.89% upside)

Analyst Consensus: Buy